TY - JOUR A2 - Bilhim，蒂亚戈AU - 高桥弘明AU - 森健作AU - 关野，雄AU - 奥村，俊AU - 桧山，隆AU - 福田，邦明AU - 长谷川，直行非盟 - 酒井，雅文AU -菊池，俊介AU - 武井，阳平AU - Iizumi，隆AU - 樱井秀行AU - 南，押尾PY - 2019 DA - 2019年7月4日TI - 在患者血管造影结果与肝癌以前治疗使用质子束治疗的SP -3580379 VL - 2019 AB - 考虑到在利用质子束治疗（PBT）肝细胞癌（HCC）的兴趣越来越大，有可能是肝动脉化疗栓塞（TACE）可用于谁先前经过PBT选择的患者。然而，这些案件可能是技术上的挑战，以治疗和需要适当的准备。因此，我们的目的是确定在此设置造影结果。我们回顾性调查31例（28名男3名女，平均年龄69岁，范围：43-84岁）谁接受该PBT（2007年7月后复发的肝癌肝动脉造影加TACE或动脉灌注化疗（TAI）至2018年6月）。我们发现4个造影检查结果，我们推测均与以前的PBT。18名患者经历复发的照域，以及被照射场外部13名患者经历复发。29例患者接受TACE，只有2例患者进行TAI。的前处理PBT的平均数目为1.3±0.6（范围：1-4）。 The median interval from the earliest PBT treatment to hepatic angiography was 559 days (range: 34–5,383 days), and the median interval from the latest PBT treatment to hepatic angiography was 464 days (range: 34–5,383 days). Abnormal staining of the irradiated liver parenchyma was observed in 22 patients, which obscured the angiographic tumor staining in 4 patients. Development of a tortuous tumor feeder vessel was observed in 13 patients. Development of an extrahepatic collateral pathway was observed in 7 patients. Development of an arterioportal or arteriovenous shunt was observed in 4 patients. Based on these findings, we conclude that PBT was associated with various angiographic findings during subsequent transarterial chemotherapy for recurrent HCC, and familiarity with these findings will be important in developing appropriate treatment plans. SN - 1687-8450 UR - https://doi.org/10.1155/2019/3580379 DO - 10.1155/2019/3580379 JF - Journal of Oncology PB - Hindawi KW - ER -